Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Neuropathic Pain & Neurodegeneration.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EPHB1 drug discovery. Select your modality below to access sequence-verified reagents designed for selective targeting and cross-species evaluation.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPHB1 ECD-Fc / Kinase Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View EPHB1 Products |
| Gene Delivery | EPHB1 Lentivirus Premade Particles Full-length human EPHB1 ORF (NM_004441) for stable cell line construction. High titer (>10^8 TU/ml). |
View EPHB1 Products |
| Benchmark Ab | Anti-EPHB1 Reference Antibody Recombinant monoclonal positive control. Sequence-defined for binding assay standardization. |
View EPHB1 Products |
| Validator | EPHB1 siRNA Set Three unique sequence-verified siRNAs (19-21 nt) for knockdown verification and specificity controls. |
View EPHB1 Products |
| Ligand | EFNB1 (Ephrin-B1) ECD-Fc Cognate transmembrane ligand for functional binding and competition assays. |
View EFNB1 Products |
| Selectivity Control | EPHB2 ECD-Fc Closest paralog (85% ECD identity). Critical for off-target screening and specificity validation. |
View EPHB2 Products |
| Vascular Partner | EPHB4 ECD-Fc Angiogenesis pathway partner. For combination therapy screening and dual-targeting assays. |
View EPHB4 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity (EPHB2/EPHB4 cross-reactivity) | Homolog Panel Proteins: EPHB1, EPHB2, EPHB4 ECD-Fc all >95% purity, matched HEK293 expression system. Mass spec verified molecular weight. |
| Cross-species Cyno/Mouse Evaluation | Ortholog Protein Trio: Human, Cynomolgus, and Mouse EPHB1 ECD-Fc available with identical domain boundaries. Sequence verified >98% identity. |
| Ligand Competition & Binding Epitope | EFNB1 ECD-Fc Pair: Native conformation ligand for competitive binding SPR/BLI. Endotoxin controlled (<0.1EU/μg) for sensitive cell assays. |
| ADC Internalization Validation | Lentivirus Expression System: Generate high-density EPHB1+ stable cells (MCF7, CHO-K1 backgrounds). >95% transduction efficiency verified by flow cytometry. |
| False Positive Elimination | Validated siRNA Toolkit: >70% mRNA knockdown efficiency guaranteed. Include negative control (scrambled) and positive control (GAPDH). |
| Lack of Controls | Sequence-defined benchmark antibodies included for SPR/FACS baseline establishment. |
Live EPHB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The EPHB1 therapeutic landscape represents a strategic whitespace opportunity within the Eph receptor family. While pan-Eph inhibitors have dominated historical development efforts, the field is pivoting toward subtype-selective modalities to mitigate on-target neurological toxicities. EPHB1 is emerging as a differentiated target across multiple therapeutic areas: oncology (colorectal, pancreatic, gastric, medulloblastoma, NSCLC), neuropathic pain and neuro-inflammation, neurodegeneration (axon guidance and synaptic plasticity), and fibrotic diseases. Current R&D emphasizes two vectors: (1) Oncology applications leveraging EPHB1's role in tumor angiogenesis and microenvironment remodeling, and (2) Neurological programs targeting pain signaling and regenerative mechanisms. As first-generation biologics advance through preclinical validation, the critical differentiator will be the ability to distinguish EPHB1 from highly homologous family members (EPHB2/EPHB4) while maintaining cross-species binding for toxicology studies. The convergence of ADC technology with RTK selectivity requirements positions EPHB1 as an emerging target for solid tumor payloads requiring efficient internalization. Early pipelines are exploring biologics that exploit EPHB1-forward signaling blockade and ADC modalities leveraging receptor-mediated internalization. The next wave of R&D is targeting extreme selectivity to bypass historical off-target toxicities associated with broader Ephrin receptor inhibition, alongside rational combination strategies with chemotherapy, immunotherapy, and anti-angiogenic agents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Anti-EPHB1) | Emerging Biotechs, ADC specialty platforms | Solid Tumors (Colorectal, NSCLC, Pancreatic) | Internalization Assay requiring high-purity ECD-Fc for binding confirmation and lentivirus for stable reporter cell lines |
| Monoclonal Antibody (Selective/Blocking) | Mid-size Pharma, Academic labs | Solid Tumors (Gastric, Brain), Neurodegeneration | Subfamily Specificity Panel: Need EPHB2/EPHB4 homologs for counter-screening; Ligand-Blocking Validation (Need HEK293-expressed ECD-Fc and EFNB1) |
| Bispecific (e.g., EPHB1 x VEGFR) | Oncology-Focused Biotech | Angiogenic Cancers | Dual-Antigen Binding Validation using ortholog proteins to verify species cross-reactivity |
| Small Molecule Inhibitor | Early-stage Biotechs, Genentech, NCI | Neuropathic Pain, Neuro-inflammation, Refractory Cancers | Kinase Selectivity Assay (Need High-Purity Mutant vs WT Kinase Domains) |
| Peptide Antagonists | Emerging Biopharma | Tissue Fibrosis | Binding Affinity/SPR (Need strictly quality-controlled ECD antigens) |